UNSPSC 51312103: Olopatadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D27V6190PM, chemically known as 11-((z)-3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid but generally known as olopatadine, which bears US NIH Compound Identifier 5281071. European Medicines Agency schedules Olopatadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09431MIG.

UNSPSC 51312103 Olopatadine is a Commodity code that nominally identifies a single pharmaceutical product, but recent state and local opportunities show procurement activity across a broader pharmaceutical and health-system supply spectrum. State and local governments are soliciting under this code designation for naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through direct-to-manufacturer prescription programs and cooperative purchasing arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The procurement mix spans community health initiatives, pharmacy benefit program optimization, and standardized pharmaceutical supply chains for state and local facilities.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026, closing July 26, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the contract carries a two-year initial term with one-year renewal option and FEMA compliance requirements. Texas HHS Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, exploring vendor capacity to establish relationships outside traditional pharmacy benefit manager and wholesaler channels. Minnesota's MMCAP issued RFP S1070000015802 in January 2026, closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and vendors required to maintain $5 million commercial general liability coverage and comply with cGMP and Drug Supply Chain Security Act standards.